$AZTA

BROOKS AUTOMATION INC

CIK:0000933974|SEC Filings

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenue
Total revenue	$ 161,178	$ 143,855	$ 454,615	$ 434,629
Cost of revenue
Total cost of revenue	88,822	77,451	256,518	236,623
Gross profit	72,356	66,404	198,097	198,006
Operating expenses
Research and development	8,853	7,417	27,475	22,132
Selling, general and administrative	67,168	60,083	195,666	199,854
Impairment of goodwill and intangible assets	0	0	149,083	0
Restructuring charges	513	754	3,078	4,765
Total operating expenses	76,534	68,254	375,302	226,751
Operating loss	(4,178)	(1,850)	(177,205)	(28,745)
Other income (expense)
Interest income, net	3,825	4,973	13,310	13,760
Other income (expense), net	1,199	(820)	5,337	1,542
Income (loss) from continuing operations before income taxes	846	2,303	(158,558)	(13,443)
Income tax expense	2,375	2,635	5,182	13,752
Loss from continuing operations	(1,529)	(332)	(163,740)	(27,195)
Income (loss) from discontinued operations, net of tax	3,985	(47,655)	(10,034)	(79,445)
Net income (loss)	$ 2,456	$ (47,987)	$ (173,774)	$ (106,640)
Basic net income (loss) per share:
Loss from continuing operations (in dollars per share)	$ (0.03)	$ (0.01)	$ (3.58)	$ (0.59)
Income (loss) from discontinued operations, net of tax (in dollars per share)	0.09	(1.04)	(0.22)	(1.74)
Basic net income (loss) per share (in dollars per share)	0.05	(1.05)	(3.80)	(2.33)
Diluted net income (loss) per share:
Income (loss) from continuing operations (in dollars per share)	(0.03)	(0.01)	(3.58)	(0.59)
Income (loss) from discontinued operations, net of tax (in dollars per share)	0.09	(1.04)	(0.22)	(1.74)
Diluted net income (loss) per share (in dollars per share)	$ 0.05	$ (1.05)	$ (3.80)	$ (2.33)
Weighted average shares used in computing net income (loss) per share:
Basic (in shares)	45,286	45,780	45,759	45,712
Diluted (in shares)	45,286	45,780	45,759	45,712
Products
Revenue
Total revenue	$ 41,259	$ 39,387	$ 119,985	$ 125,169
Cost of revenue
Total cost of revenue	25,018	19,572	71,889	68,607
Services
Revenue
Total revenue	119,919	104,468	334,630	309,460
Cost of revenue
Total cost of revenue	$ 63,804	$ 57,879	$ 184,629	$ 168,016

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities
Net loss	$ (173,774)	$ (106,640)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	41,230	46,775
Impairment of goodwill and intangible assets	149,083	0
Non-cash gain from settlement of preexisting contractual relationship	(3,858)	0
Loss on assets held for sale	9,491	92,706
Inventory write-downs and other non-cash items	1,301	3,866
Stock-based compensation	15,232	16,716
Amortization and accretion on marketable securities	(1,088)	(1,318)
Deferred income taxes	(3,563)	(20,385)
Loss on disposals of property, plant and equipment	14	759
Changes in operating assets and liabilities:
Accounts receivable	4,073	38,799
Inventories	(9,501)	(9,998)
Accounts payable	(655)	(365)
Deferred revenue	1,986	7,156
Accrued warranty and retrofit costs	84	38
Accrued compensation and tax withholdings	(3,816)	3,604
Accrued restructuring costs	26	(51)
Other assets and liabilities	9,540	(1,651)
Net cash provided by operating activities	35,805	70,011
Cash flows from investing activities
Purchases of property, plant and equipment	(20,234)	(25,997)
Purchases of marketable securities	(365,358)	(312,990)
Sales and maturities of marketable securities	295,489	242,527
Acquisition of UK Biocentre, net of cash acquired	(11,150)	0
Proceeds from other investment	0	2,130
Net investment hedge settlement	0	3,043
Deposit received for the sale of B Medical Systems business	28,000	0
Net cash used in investing activities	(73,253)	(91,287)
Cash flows from financing activities
Proceeds from issuance of common stock	1,178	1,553
Payments of finance leases	(583)	(585)
Withholding tax payments on net share settlements on equity awards	(2,521)	0
Excise tax payment for settled share repurchases	0	(11,376)
Share repurchases	(50,046)	0
Net cash used in financing activities	(51,972)	(10,408)
Effects of exchange rate changes on cash, cash equivalents and restricted cash	(2,594)	4,510
Net decrease in cash, cash equivalents and restricted cash	(92,014)	(27,174)
Cash, cash equivalents and restricted cash, beginning of period	296,685	320,990
Cash, cash equivalents and restricted cash, end of period	204,671	293,816
Supplemental disclosures:
Cash paid for income taxes, net	7,017	2,243
Purchases of property, plant and equipment included in accounts payable and accrued expenses	6,978	4,652
Cash and cash equivalents of continuing operations	189,654
Cash included in current assets held for sale	8,363
Short-term restricted cash	2,414
Long-term restricted cash included in other assets	4,240
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows	$ 204,671	$ 293,816

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Sep. 30, 2025
Current assets
Cash and cash equivalents	$ 189,654	$ 279,783
Short-term marketable securities	136,143	61,137
Accounts receivable, net of allowance for expected credit losses ($3,842 and $4,649, respectively)	143,675	142,181
Inventories	79,082	74,956
Short-term restricted cash	2,414	2,359
Refundable income taxes	5,846	9,728
Prepaid expenses and other current assets	53,150	64,660
Current assets held for sale	71,387	73,535
Total current assets	681,351	708,339
Property, plant and equipment, net	172,427	153,954
Long-term marketable securities	196,087	201,585
Long-term deferred tax assets	494	726
Operating lease right-of-use assets	61,421	54,048
Goodwill	547,457	702,395
Intangible assets, net	85,688	101,814
Long-term income taxes receivable	45,600	45,600
Other assets	8,997	6,115
Noncurrent assets held for sale	76,689	85,006
Total assets	1,876,211	2,059,582
Current liabilities
Accounts payable	39,381	37,722
Deferred revenue	36,041	31,569
Derivative liability	28,435	33,420
Accrued warranty and retrofit costs	4,047	4,713
Accrued compensation and benefits	30,965	35,799
Customer deposits	35,355	26,499
Accrued income taxes payable	6,775	9,416
Deposit received for the sale of B Medical Systems business	28,000	0
Accrued expenses and other current liabilities	34,249	30,268
Current liabilities held for sale	29,326	28,268
Total current liabilities	272,574	237,674
Long-term deferred tax liabilities	15,836	18,245
Long-term operating lease liabilities	53,967	51,244
Other long-term liabilities	10,725	11,142
Noncurrent liabilities held for sale	12,980	14,291
Total liabilities	366,082	332,596
Stockholders' equity
Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding	0	0
Common stock, $0.01 par value - 125,000,000 shares authorized, 57,226,616 shares issued and 43,764,747 shares outstanding at June 30, 2026; 59,320,848 shares issued and 45,858,979 shares outstanding at September 30, 2025	572	594
Additional paid-in capital	493,071	529,605
Accumulated other comprehensive loss	(28,740)	(22,213)
Treasury stock, at cost - 13,461,869 shares at June 30, 2026 and September 30, 2025	(200,956)	(200,956)
Retained earnings	1,246,182	1,419,956
Total stockholders' equity	1,510,129	1,726,986
Total liabilities and stockholders' equity	$ 1,876,211	$ 2,059,582